InsidersTradesSigma
Follow the 에스케이바이오팜 stock price and the full management transaction log of the company, a listed issuer based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 에스케이바이오팜 has published 5 reports. Market capitalisation: €6,312bn. The latest transaction was filed on 31 August 2026 (Purchase). Among the most active insiders: SK. Every trade is free.
5
Insider Decl.
n/a
Thresholds
€719m
3 ops.
Buy Volume
n/a
1 ops.
Sell Volume
18Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,168 of 29,063 companies
66.0
score / 100
Value39
Quality93
FCF yld2.2%
Earn yld3.9%
EV/EBITDA39.1x
ROE48%
Gross mgn94%
Net mgn38%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Acerca de 에스케이바이오팜
SK Biopharmaceuticals es una empresa del sector de la salud y farmacéutico, que cotiza en la bolsa XKRX. Se centra en el desarrollo de tratamientos innovadores para trastornos neurológicos.